Robert Wilson - Madrigal Pharmaceuticals Independent Director
| MDGL Stock | USD 193.33 1.05 0.54% |
Director
Mr. Robert N. Wilson is Independent Director of Synta Pharmaceuticals Corporationration Mr. Wilson was a member of our Board of Directors since June 2003. Mr. Wilson is Chairman of MEVION Medical Systems, a medical device company. Prior to his association with MEVION, Mr. Wilson was Chairman of Caxton Health Holdings, LLC, from 2004 through 2007 and was Vice Chairman of the Board of Directors of Johnson Johnson, a manufacturer of healthcare products, from 1989 until 2003. Mr. Wilson had joined Johnson Johnson in 1964. Mr. Wilson is also a director of Hess Corporationrationration, a publicly traded integrated oil and gas company and Charles Schwab Corporationrationration, a publicly traded financial services company. He previously served on the Board of Directors of Vivus, Inc., a publicly traded biopharmaceutical company. since 2003.
| Age | 75 |
| Tenure | 21 years |
| Address | Four Tower Bridge, West Conshohocken, PA, United States, 19428 |
| Phone | 267 824 2827 |
| Web | https://www.madrigalpharma.com |
Robert Wilson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Wilson against Madrigal Pharmaceuticals stock is an integral part of due diligence when investing in Madrigal Pharmaceuticals. Robert Wilson insider activity provides valuable insight into whether Madrigal Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Madrigal Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Madrigal Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Wilson over six months ago Payment of 1361 shares by Robert Wilson of Allegiant Travel subject to Rule 16b-3 | ||
Robert Wilson over six months ago Exercise or conversion by Robert Wilson of 5244 shares of Charles Schwab subject to Rule 16b-3 | ||
Robert Wilson over six months ago Sale by Robert Wilson of 1000 shares of Allegiant Travel |
Madrigal Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4741) % which means that it has lost $0.4741 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2398) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals' management efficiency ratios could be used to measure how well Madrigal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.61. The value of Return On Capital Employed is expected to slide to -0.77. At this time, Madrigal Pharmaceuticals' Total Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 3.3 M this year, although the value of Non Currrent Assets Other will most likely fall to about 719.9 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| David McGirr | X4 Pharmaceuticals | 63 | |
| Lawson Macartney | Viking Therapeutics | 60 | |
| Peter Bains | Mereo BioPharma Group | 61 | |
| MD FACP | Hepion Pharmaceuticals | N/A | |
| Michael Wyzga | Mereo BioPharma Group | 63 | |
| Kenneth Hoberman | TG Therapeutics | 53 | |
| Matthew Foehr | Viking Therapeutics | 45 | |
| Mark Schoenebaum | TG Therapeutics | 45 | |
| Arnold Lippa | Hepion Pharmaceuticals | 70 | |
| Sanford Hillsberg | Iovance Biotherapeutics | 68 | |
| Dawn Svoronos | PTC Therapeutics | 71 | |
| Kunal Kashyap | Mereo BioPharma Group | 52 | |
| Mary Gray | Sarepta Therapeutics | 65 | |
| David Southwell | PTC Therapeutics | 57 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Athena Countouriotis | Iovance Biotherapeutics | 46 | |
| Gary Bridger | X4 Pharmaceuticals | N/A | |
| Geoffrey McDonough | PTC Therapeutics | 45 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Yann Echelard | TG Therapeutics | 54 | |
Management Performance
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.47 |
Madrigal Pharmaceuticals Leadership Team
Elected by the shareholders, the Madrigal Pharmaceuticals' board of directors comprises two types of representatives: Madrigal Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Madrigal. The board's role is to monitor Madrigal Pharmaceuticals' management team and ensure that shareholders' interests are well served. Madrigal Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Madrigal Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Hare, Senior Management | ||
| Remy Sukhija, VP Officer | ||
| Mardi Dier, Principal CFO | ||
| David Milligan, Independent Director | ||
| Richard Levy, Director | ||
| PharmD MBA, Senior Affairs | ||
| Chen Schor, President CEO, Director | ||
| William Sibold, President CEO | ||
| Ronald Filippo, Chief Officer | ||
| William Reardon, Independent Director | ||
| Paul MD, Chairman CEO | ||
| Edward Chiang, Senior Operations | ||
| Clint Wallace, Chief Officer | ||
| James Daly, Independent Director | ||
| Bruce Kovner, Independent Director | ||
| Alex Howarth, Executive Officer | ||
| Frederick Craves, Lead Independent Director | ||
| Paul Friedman, Independent Director | ||
| Rebecca Taub, Founder, Chief Medical Officer, Executive Vice President Research & Development and Director | ||
| Marc Schneebaum, CFO, Senior Vice President | ||
| Robert Wilson, Independent Director | ||
| Donald Kufe, Independent Director | ||
| Kenneth Bate, Director | ||
| Rebecca MD, Chief Founder | ||
| Robert Waltermire, Chief Officer | ||
| Scott Morenstein, Director | ||
| Wendy Rieder, Senior Vice President General Counsel | ||
| Keith Gollust, Chairman of the Board | ||
| Tina Ventura, Chief Officer | ||
| Kianoush Motesharei, Senior Development | ||
| Brian JD, Senior Counsel |
Madrigal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Madrigal Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 3.33 B | ||||
| Shares Outstanding | 20.97 M | ||||
| Shares Owned By Insiders | 9.24 % | ||||
| Shares Owned By Institutions | 94.86 % | ||||
| Number Of Shares Shorted | 3.41 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 12.24 X | ||||
| EBITDA | (379.97 M) |
Madrigal Pharmaceuticals Investors Sentiment
The influence of Madrigal Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Madrigal. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Madrigal Pharmaceuticals' public news can be used to forecast risks associated with an investment in Madrigal. The trend in average sentiment can be used to explain how an investor holding Madrigal can time the market purely based on public headlines and social activities around Madrigal Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Madrigal Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Madrigal Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Madrigal Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Madrigal Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Madrigal Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Madrigal Pharmaceuticals' short interest history, or implied volatility extrapolated from Madrigal Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Madrigal Stock analysis
When running Madrigal Pharmaceuticals' price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.99) | Return On Assets (0.47) | Return On Equity (1.24) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.